Screening for Anti-Inflammation Quality Markers of Lianhua Qingwen Capsule Based on Network Pharmacology, UPLC, and Biological Activity
Influenza is a common respiratory infectious disease. In China, Lianhua Qingwen capsule (LHQWC), a drug with significant clinical efficacy and few side effects, is commonly used to treat influenza. However, the composition of LHQWC is complicated, and currently used quality control methods cannot en...
Main Authors: | Yongfeng Zhou, Ming Niu, Dingkun Zhang, Zhenxing Liu, Qinghua Wu, Jiang Chen, Haizhu Zhang, Ping Zhang, Jin Pei |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-06-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.648439/full |
Similar Items
-
The mechanisms and clinical application of Traditional Chinese Medicine Lianhua-Qingwen capsule
by: Xuhui Shen, et al.
Published: (2021-10-01) -
Clinical applications and pharmacological research progress of Lianhua Qingwen capsules/granules
by: Zhenhua Jia, et al.
Published: (2021-04-01) -
A meta-analysis for Lianhua Qingwen on the treatment of Coronavirus disease 2019 (COVID-19)
by: Jieqin Zhuang, et al.
Published: (2021-08-01) -
Meta-analysis of the efficacy and safety of Lianhua Qingwen combined with western medicine in the treatment of common patients with new coronary pneumonia
by: Wen-Bin Zhang, et al.
Published: (2020-07-01) -
Lianhua Qingwen prescription for Coronavirus disease 2019 (COVID-19) treatment: Advances and prospects
by: Liu-Cheng Li, et al.
Published: (2020-10-01)